Oncoinvent

Oncoinvent reports the recruitment of 54 patients, representing 50% of the planned study population for the phase‑2 trial of Radspherin in peritoneal carcinomatosis caused by ovarian cancer. The randomized, controlled trial compares Radspherin after complete surgical resection and preoperative chemotherapy with standard treatment; ten centers in the US and Europe are currently active and additional sites are being opened. The 28 patients enrolled so far this year exceed the planned recruitment for 2025, and earlier studies showed good tolerability with no dose‑limiting toxicity. Shareholder information: the stock trades at $4.57 with a market capitalization of $20.46m, the price is near its 52‑week low; analyst targets range from $5.09 to $7.27, while the company—despite negative free cash flows—holds more liquid assets than short‑term liabilities. » More on de.investing.com